This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

SMILE

Authoring team

1556 patients with anterior myocardial infarction were enrolled in the trial within 24 hr of the onset of symptoms.

Double blind randomisation assigned patients to placebo or zofenopril (initially 7.5 mg, with a target of 30 mg bd). Treatment with zofenopril was continued for 6 weeks.

Short-term and long-term outcome was improved in patients who received this short dose of ACE inhibitor. The risk of mortality was reduced by 29% at one year in the zofenopril group.

Reference:

  • Ambrosioni, E. et al. (1995). The effect of the angiotensin-converting-enzyme inhibitor Zofenopril on mortality and morbidity after anterior myocardial infarction. NEJM, 322(2), 80-85.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.